Cargando…

Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study

Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakhleh, Afif, Othman, Areen, Masri, Amin, Zloczower, Moshe, Zolotov, Sagit, Shehadeh, Naim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604468/
https://www.ncbi.nlm.nih.gov/pubmed/37893063
http://dx.doi.org/10.3390/biomedicines11102689
_version_ 1785126842667106304
author Nakhleh, Afif
Othman, Areen
Masri, Amin
Zloczower, Moshe
Zolotov, Sagit
Shehadeh, Naim
author_facet Nakhleh, Afif
Othman, Areen
Masri, Amin
Zloczower, Moshe
Zolotov, Sagit
Shehadeh, Naim
author_sort Nakhleh, Afif
collection PubMed
description Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015 and 9/2020. Demographic, clinical, and laboratory data were obtained from electronic medical records. Outpatient mortality was monitored until 12/2022. Results: Of 71 T2DM patients admitted with DKA, 16 (22.5%) were on SGLT2 inhibitor treatment upon admission. SGLT2 inhibitor users had a higher BMI and were less likely to be treated with insulin. During hospitalization, the rates of acute kidney injury, concomitant infections, and inpatient mortality among SGLT2 inhibitor users were comparable to non-users. The median follow-up period was 35.1 months for the SGLT2 inhibitor users and 36.7 months for non-users. The long-term mortality from any cause was lower among the SGLT2 inhibitor users (12.5% vs. 52.7%, p = 0.004). In Cox regression analysis, SGLT2 inhibitor use was associated with a lower risk of long-term mortality from any cause (HR = 0.19, p = 0.04). Conclusion: T2DM patients with DKA who received SGLT2 inhibitors had lower long-term mortality from any cause compared to those who did not receive SGLT2 inhibitors.
format Online
Article
Text
id pubmed-10604468
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106044682023-10-28 Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study Nakhleh, Afif Othman, Areen Masri, Amin Zloczower, Moshe Zolotov, Sagit Shehadeh, Naim Biomedicines Article Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015 and 9/2020. Demographic, clinical, and laboratory data were obtained from electronic medical records. Outpatient mortality was monitored until 12/2022. Results: Of 71 T2DM patients admitted with DKA, 16 (22.5%) were on SGLT2 inhibitor treatment upon admission. SGLT2 inhibitor users had a higher BMI and were less likely to be treated with insulin. During hospitalization, the rates of acute kidney injury, concomitant infections, and inpatient mortality among SGLT2 inhibitor users were comparable to non-users. The median follow-up period was 35.1 months for the SGLT2 inhibitor users and 36.7 months for non-users. The long-term mortality from any cause was lower among the SGLT2 inhibitor users (12.5% vs. 52.7%, p = 0.004). In Cox regression analysis, SGLT2 inhibitor use was associated with a lower risk of long-term mortality from any cause (HR = 0.19, p = 0.04). Conclusion: T2DM patients with DKA who received SGLT2 inhibitors had lower long-term mortality from any cause compared to those who did not receive SGLT2 inhibitors. MDPI 2023-10-01 /pmc/articles/PMC10604468/ /pubmed/37893063 http://dx.doi.org/10.3390/biomedicines11102689 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nakhleh, Afif
Othman, Areen
Masri, Amin
Zloczower, Moshe
Zolotov, Sagit
Shehadeh, Naim
Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title_full Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title_fullStr Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title_full_unstemmed Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title_short Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
title_sort clinical outcomes of diabetic ketoacidosis in type 2 diabetes patients with and without sglt2 inhibitor treatment: a retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604468/
https://www.ncbi.nlm.nih.gov/pubmed/37893063
http://dx.doi.org/10.3390/biomedicines11102689
work_keys_str_mv AT nakhlehafif clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy
AT othmanareen clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy
AT masriamin clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy
AT zloczowermoshe clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy
AT zolotovsagit clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy
AT shehadehnaim clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy